vs

Side-by-side financial comparison of ASSEMBLY BIOSCIENCES, INC. (ASMB) and SurgePays, Inc. (SURG). Click either name above to swap in a different company.

SurgePays, Inc. is the larger business by last-quarter revenue ($16.2M vs $10.8M, roughly 1.5× ASSEMBLY BIOSCIENCES, INC.). ASSEMBLY BIOSCIENCES, INC. runs the higher net margin — -85.2% vs -85.6%, a 0.4% gap on every dollar of revenue. On growth, SurgePays, Inc. posted the faster year-over-year revenue change (68.7% vs 57.6%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

SurgePays, Inc. is a U.S.-headquartered fintech and telecommunications company focused on serving underbanked and low-income communities across the country. It offers prepaid wireless plans, reloadable debit cards, digital banking solutions, and daily consumer products through a nationwide network of independent local retail partners such as convenience stores.

ASMB vs SURG — Head-to-Head

Bigger by revenue
SURG
SURG
1.5× larger
SURG
$16.2M
$10.8M
ASMB
Growing faster (revenue YoY)
SURG
SURG
+11.1% gap
SURG
68.7%
57.6%
ASMB
Higher net margin
ASMB
ASMB
0.4% more per $
ASMB
-85.2%
-85.6%
SURG

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASMB
ASMB
SURG
SURG
Revenue
$10.8M
$16.2M
Net Profit
$-9.2M
$-13.9M
Gross Margin
-14.8%
Operating Margin
-100.9%
-79.1%
Net Margin
-85.2%
-85.6%
Revenue YoY
57.6%
68.7%
Net Profit YoY
4.3%
30.0%
EPS (diluted)
$-0.72
$-0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASMB
ASMB
SURG
SURG
Q4 25
$16.2M
Q3 25
$10.8M
$18.7M
Q2 25
$9.6M
$11.5M
Q1 25
$9.4M
$10.6M
Q4 24
$7.4M
$9.6M
Q3 24
$6.8M
$4.8M
Q2 24
$8.5M
$15.1M
Q1 24
$5.8M
$31.4M
Net Profit
ASMB
ASMB
SURG
SURG
Q4 25
$-13.9M
Q3 25
$-9.2M
$-7.5M
Q2 25
$-10.2M
$-7.1M
Q1 25
$-8.8M
$-7.6M
Q4 24
$-19.8M
Q3 24
$-9.6M
$-14.3M
Q2 24
$-11.2M
$-12.9M
Q1 24
$-9.1M
$1.2M
Gross Margin
ASMB
ASMB
SURG
SURG
Q4 25
-14.8%
Q3 25
-13.9%
Q2 25
-23.0%
Q1 25
-27.8%
Q4 24
-117.0%
Q3 24
-164.2%
Q2 24
-22.8%
Q1 24
26.0%
Operating Margin
ASMB
ASMB
SURG
SURG
Q4 25
-79.1%
Q3 25
-100.9%
-37.2%
Q2 25
-115.2%
-59.1%
Q1 25
-105.5%
-71.7%
Q4 24
-209.0%
Q3 24
-160.1%
-299.4%
Q2 24
-143.0%
-72.1%
Q1 24
-185.5%
5.6%
Net Margin
ASMB
ASMB
SURG
SURG
Q4 25
-85.6%
Q3 25
-85.2%
-40.1%
Q2 25
-105.9%
-61.5%
Q1 25
-93.6%
-72.2%
Q4 24
-206.5%
Q3 24
-140.4%
-299.3%
Q2 24
-130.7%
-85.3%
Q1 24
-156.9%
3.9%
EPS (diluted)
ASMB
ASMB
SURG
SURG
Q4 25
$-0.68
Q3 25
$-0.72
$-0.38
Q2 25
$-1.33
$-0.36
Q1 25
$-1.17
$-0.38
Q4 24
$-1.07
Q3 24
$-1.51
$-0.73
Q2 24
$-1.98
$-0.66
Q1 24
$-1.66
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASMB
ASMB
SURG
SURG
Cash + ST InvestmentsLiquidity on hand
$22.5M
$1.7M
Total DebtLower is stronger
$13.3M
Stockholders' EquityBook value
$182.7M
$-15.3M
Total Assets
$240.0M
$8.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASMB
ASMB
SURG
SURG
Q4 25
$1.7M
Q3 25
$22.5M
$2.5M
Q2 25
$24.0M
$4.4M
Q1 25
$23.4M
$5.4M
Q4 24
$38.3M
$11.8M
Q3 24
$28.5M
$23.7M
Q2 24
$19.2M
Q1 24
$18.7M
Total Debt
ASMB
ASMB
SURG
SURG
Q4 25
$13.3M
Q3 25
$12.0M
Q2 25
$9.6M
Q1 25
$3.6M
Q4 24
$4.0M
Q3 24
$4.4M
Q2 24
$4.8M
Q1 24
$5.2M
Stockholders' Equity
ASMB
ASMB
SURG
SURG
Q4 25
$-15.3M
Q3 25
$182.7M
$-6.4M
Q2 25
$18.1M
$116.1K
Q1 25
$27.1M
$7.8M
Q4 24
$33.4M
$15.3M
Q3 24
$26.0M
$33.2M
Q2 24
$34.7M
$46.2M
Q1 24
$32.6M
$56.0M
Total Assets
ASMB
ASMB
SURG
SURG
Q4 25
$8.5M
Q3 25
$240.0M
$14.5M
Q2 25
$80.8M
$15.2M
Q1 25
$99.0M
$15.7M
Q4 24
$119.2M
$24.0M
Q3 24
$100.3M
$41.5M
Q2 24
$115.3M
$56.4M
Q1 24
$119.9M
$69.6M
Debt / Equity
ASMB
ASMB
SURG
SURG
Q4 25
Q3 25
Q2 25
82.67×
Q1 25
0.46×
Q4 24
0.26×
Q3 24
0.13×
Q2 24
0.10×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASMB
ASMB
SURG
SURG
Operating Cash FlowLast quarter
$-15.1M
$-3.6M
Free Cash FlowOCF − Capex
$-15.2M
FCF MarginFCF / Revenue
-140.7%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASMB
ASMB
SURG
SURG
Q4 25
$-3.6M
Q3 25
$-15.1M
$-4.6M
Q2 25
$-16.8M
$-6.1M
Q1 25
$-23.4M
$-7.0M
Q4 24
$-51.1M
$-7.9M
Q3 24
$-15.2M
$-13.3M
Q2 24
$-17.1M
$-4.1M
Q1 24
$-18.4M
$4.0M
Free Cash Flow
ASMB
ASMB
SURG
SURG
Q4 25
Q3 25
$-15.2M
Q2 25
Q1 25
Q4 24
$-51.1M
Q3 24
Q2 24
$-17.1M
Q1 24
$-18.4M
FCF Margin
ASMB
ASMB
SURG
SURG
Q4 25
Q3 25
-140.7%
Q2 25
Q1 25
Q4 24
-695.2%
Q3 24
Q2 24
-200.6%
Q1 24
-317.7%
Capex Intensity
ASMB
ASMB
SURG
SURG
Q4 25
Q3 25
0.4%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.4%
Q3 24
0.0%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
ASMB
ASMB
SURG
SURG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
3.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons